Shanghai Lishan Biopharmaceuticals

Shanghai Lishan Biopharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to address unmet medical needs in both hematological malignancies and solid tumors. Their lead program, LS-001, is a CD19-targeted CAR-T therapy currently undergoing clinical evaluation for B-cell lymphoma. Lishan Biopharmaceuticals leverages a proprietary cell engineering platform designed to enhance the safety, persistence, and efficacy of engineered T-cells. By targeting antigens such as BCMA, Claudin 18.2, and GPC3, the company is expanding its pipeline to treat a variety of difficult-to-treat cancers.